

Anti-KIR Antibody (Lirilumab)

Introduction

Lirilumab (IPH2102) is anti-KIR A monoclonal antibody with anti-tumor activity. Lirilumab is used in the study of leukemia and squamous cell carcinoma of the head and neck (SCCHN).

Product parameters

Alternative Names	IPH 2101, IPH2101, 1-7F9
Target Accession	P55040
Target	KIR
CAS number	1000676-41-4
Molecular Weight	145.52 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

